Objectives: Cryoplasty has been proposed as a different therapy to address the problems of recurrent lesions. We reviewed our experience with cryoplasty to determine its outcome treating patients with lesions in native vessels and within stents. Methods: A retrospective review of all patients undergoing cryotherapy between 2004 and 2008 was conducted. Patency was defined by at least one of the following criteria: flow through the vessel demonstrated by angiography or duplex ultrasonography, maintenance of an ankle-brachial index (ABI) greater than 0.10 above the preprocedural value, or maintenance of a palpable pedal pulse that was absent before the procedure in an asymptomatic patient. Patency, limb salvage, symptomatic improvement, and freedom from surgical bypass were determined with Kaplan-Meier survival analysis and compared by log-rank testing. Multivariate analysis was performed by Cox proportionalhazards regression. Results: Eighty-eight cryoplasty procedures were performed in 71 patients, with 35 procedures for in-stent restenosis and 37 for native vessel disease. Sixteen of 88 procedures in grafts were excluded from analysis secondary to combined disease process and/or bypass graft stenosis. Lesions treated with cryoplasty had an average of 2.9 prior endovascular interventions. Eighty-five percent of the lesions were described as complex (multifocal, diffuse, or occlusion) and the mean lesion length was 15 ؎ 10 cm. Initial cryoplasty technical success rate was 68% (25 of 37) for native vessels and 71% (25 of 35) for in-stent procedures. One year primary patency for the native vs stent group was 17% vs 28%, respectively (P ‫؍‬ .18). The 1-year primary assisted patency for the native vs stent group was 28% vs 47%, respectively (P ‫؍‬ .33). The 1-year secondary patency for the native vs stent group was 41% vs 57% (P ‫؍‬ .42), respectively. Freedom from claudication at 1 year for the native vs stent group was 32% vs 21% (P ‫؍‬ .80). Compared to balloon angioplasty, cryoplasty has an averaged up-cost of $1851.50 per procedure. Conclusion: Cryoplasty was used in patients with extensive disease and multiple prior interventions. Cryoplasty provided poor patency rates and poor relief from claudication at 1 year in this population. Overall, cryoplasty seems to be an expensive endovascular tool with marginal clinical improvement in our experience
Endovascular therapy for infrainguinal arterial occlusive disease has rapidly expanded over the last decade. Lower patency rates compared to open revascularization have continued to plague endovascular therapies. Restenosis occurs in 30% to 80% of patients treated with percutaneous transluminal angioplasty, 1 and in 40% of patients within 1 year of stent placement. 2 Due to recurrent stenosis, reintervention is often necessary. Cryoplasty (PolarCath Peripheral Dilatation System; Boston Scientific Corp, Natick, Mass) has been introduced as a procedure that will reduce restenosis in vessels and improve the long-term patency of the revascularization procedure. Cryoplasty was approved by the Food & Drug Administration in August of 2003 for dilation of stenosis in the peripheral vasculature of the iliac, femoral, popliteal, infrapopliteal, and renal arteries. The theory behind cryoplasty's use is that the liquid nitrous oxide which is used to inflate the procedural balloon causes the surrounding vessel to freeze at -10°C, and then the vessel is slowly rewarmed causing apoptosis to be induced at the site of intervention. 3 The induction of apoptosis by cryoplasty is thought to reduce the inflammatory response which results in a decreased likelihood of restenosis. 4 Initial research on the efficacy of cryoplasty has shown that cryoplasty is able "to restore normal arterial flow with sustained patency." 5 A large, multicenter study by Laird et al 6 shows clinical patency rates for cryoplasty to be 82.3% after 300 days and maintained at 75% after 3 years. Furthermore, Das et al 7 have shown cryoplasty to be "a safe and effective method of treating infrapopliteal disease, providing excellent acute outcomes and a high rate of limb salvage in patients with critical limb ischemia" with an amputation-survival rate of 89.3% at 180 days. While cryoplasty has been shown to decrease the rate of restenosis and increase vessel patency in these studies, the researchers did not differentiate between patients with in-stent restenosis and those with native lesions. Whether or not the data presented in these studies reflects the ability of cryoplasty to treat patients with in-stent restenosis remains unclear. We From reviewed our experience with cryoplasty to more clearly define the technical feasibility, patency, and clinical outcomes of cryoplasty.
MATERIALS AND METHODS
A retrospective review was performed on patients in whom cryoplasty therapy was used to treat lower extremity arterial occlusive disease from March 1, 2004 through May 31, 2008 . Codes on hospital charge sheets were used to identify those patients who underwent cryoplasty. Patient demographics, clinic notes, noninvasive vascular studies, angiographic findings, and operative reports were reviewed after approval by the Institutional Review Board.
During this period, 88 limbs with arterial occlusive disease were treated with cryoplasty in 71 consecutive patients. The use of cryoplasty was left to the discretion of the surgeon. The treated segments ranged from the common iliac artery to the tibial arteries. Characteristics of the treated lesions were described by lesion type (stenosis vs occlusion), stenotic lesions were further divided by distribution (isolated focal [isolated lesions Ͻ5 cm], multifocal [noncontiguous isolated lesions, which individually are Ͻ5 cm], and diffuse [contiguous lesions Ͼ5 cm]), presence of calcification, and lesion length (sum total length of treated segments, contiguous, and noncontiguous). Vessel types were defined as native artery (no prior stents or devices implanted), in-stent (treated segment within 1 cm proximal and distal of stent), graft (previous bypass grafts within the conduit and within 1 cm of proximal and distal anastomosis), or a combination of any of the preceding vessel types. Previous interventions were defined as endovascular interventions performed prior to the intervention in which cryoplasty was used. Prior bypass surgeries were defined as any open surgical bypass performed on the limb undergoing an intervention. Primary procedure was defined as the first intervention undertaken in the procedural course in which cryoplasty was used. Secondary, tertiary, or quaternary procedures were those interventions that followed the primary procedure during the same treatment. Reinterventions were defined as procedures performed at a completely separate treatment time.
All procedures were performed in an angiographic suite with the patient under local anesthesia and moderate sedation. The common femoral artery contralateral to the treated limb was the preferred means of angiographic access. After angiography and identification of an arterial lesion, patients were systemically heparinized; no IIb/IIIa inhibitors were used. The lesions were typically approached by placement of a longer sheath over the aortic bifurcation and in proximity to the lesion. Treatment was deemed technically successful if a residual stenosis of less than 30% was obtained. Initial cryoplasty technical success defines those procedures in which cryoplasty produced a residual stenosis less than 30% and after which no other therapies were used. Overall procedural success is determined by the outcome after the whole procedural course, ie, after primary and all adjunctive procedures. Stents were selectively deployed within segments of the channel for suboptimal angioplasty, defined as residual stenosis greater than 30% or flow-limiting lesions. After the procedure, patients received 75 mg clopidogrel for at least 1 month and aspirin indefinitely. Patients were allowed to resume ambulation 6 to 8 hours after the procedure and were typically discharged home the same day or within 24 hours.
Clinical follow-up at 1 month, 3 months, and 6 to 12 months after the procedure was routine and included physical examination and measurement of ankle-brachial indices. Duplex examination of the treated artery and further follow-up were obtained at the discretion of the treating surgeon. Any additional endovascular procedures to maintain or restore patency were recorded, as were all open surgical revisions, bypasses, and major amputations performed through December 31, 2008.
Patency was defined by at least one of the following criteria: flow through the vessel demonstrated by angiography or duplex ultrasonography (Ͼ50% stenosis defined by doubling of peak systolic velocity), maintenance of an ankle-brachial index (ABI) greater than 0.10 above the preprocedural value, or maintenance of a palpable pedal pulse that was absent before the procedure in an asymptomatic patient. Resolution of symptoms, per se, was not considered a confirmation of patency. Any follow-up intervention necessitating open surgical revision or bypass was reported as such and was not included in primary assisted or secondary patency. Symptomatic improvement in patients with claudication was defined as improvement in walking distance, as determined through follow-up visits; this was a qualitative measurement, not quantitative.
Continuous data are expressed as mean SD and were compared by using the t-test. Noncontinuous data are expressed as percentages and were compared by using the z-test comparison for proportions. A P value Ͻ .05 was considered statistically significant. Patency, limb salvage, symptomatic improvement, and freedom from surgical bypass were determined with Kaplan-Meier survival analysis and compared by log-rank testing. Multivariate analysis was performed by Cox proportional hazards regression. Patency is presented in terms of technical success.
RESULTS

Descriptive analysis. Seventy-one patients (88 limbs)
underwent cryoplasty for CLI, disabling claudication, or asymptomatic restenosis from March 1, 2004 through May 31, 2008. Cryoplasty was performed on 37 (42%) native arteries, 35 (40%) stented arteries, 6 (7%) bypass grafts, and 10 (11%) combination vessel types (9 native and stented arteries; 1 bypass graft and stent). The bypass graft and combination vessel types were excluded from analysis because these cohorts were too small to analyze on their own and too different to be included in one of the groups. Further analysis will focus on the native artery (native) and stented artery (stent) groups only. The mean follow-up was 14.6 months (range, 0-57 months); there was no statistical difference in follow-up duration between the two groups. Patient demographics are presented in Table I . Patients in the native group had a mean age of 67 Ϯ 10, while those in the stent group had a mean age of 65 Ϯ 11 (P ϭ .43). The majority of patients in each group were white men. Overall, there were no differences in risk factors for atherosclerosis between the two groups, except a slight trend for a higher prevalence of end-stage renal disease (ESRD) in the native group (24% native vs 10% stent; P ϭ .12). The stent group had a higher rate of previous surgical bypass procedures compared to the native group (29% stent vs 9% native; P ϭ .045).
The majority of interventions were performed for lifestyle limiting claudication (native 62% vs stent 69%; P ϭ .57). Other indications for cryoplasty were CLI (native 24% vs stent 14%; P ϭ .15) and asymptomatic restenosis (native 14% and stent 17%; P ϭ NS). All the patients who were "asymptomatic" presented for reintervention. The first intervention was performed for CLI in 6 patients and claudication in the other 5 patients. The stent group had undergone more previous interventions prior to cryoplasty than the native group (100% vs 46%; P ϭ .001). Of those patients who had undergone previous intervention, the mean number of previous endovascular interventions per patient were similar between both groups (native 2.8 vs stent 3.1; P ϭ .64).
The lesions were equally distributed throughout the lower extremity between each group (Table II) . The majority of lesions were located in the superficial femoral artery only (native 51% vs stent 51%; P ϭ NS). The native group also had three combination lesions that spanned the superficial femoral-popliteal-infrapopliteal arteries. The stent group had four combination lesions that were distributed across the iliac-common femoral artery (1), iliacsuperficial femoral artery (1), superficial femoral-infrapopliteal artery (1), and popliteal-infrapopliteal artery (1) . Lesion lengths ranged from 3 to 36 cm. The mean lesion length was similar between the native and stent group (native 14.5 cm Ϯ 9 vs stent 13.3 cm Ϯ 9.5; P ϭ .61). There was better vessel runoff in the stent group compared to the native group (2.3 Ϯ 0.8 vs 1.8 Ϯ 0.8; P ϭ .05). The native artery group lesions were 73% stenosis and 27% occlusions compared to 57% stenosis and 43% occlusions in the stent group (P ϭ .16). In addition, for both groups the majority of stenotic lesions were described as complex, ie, multifocal or diffuse.
In the native artery group, cryoplasty was used as the primary intervention in 73% (n ϭ 27 of 37) and as adjunctive intervention in 27% (n ϭ 10 of 37). The interventions performed immediately prior to cryoplasty included intraluminal angioplasty (n ϭ 6), subintimal angioplasty (n ϭ 3), and laser atherectomy (n ϭ 1). In 1 patient, cryoplasty was used as the tertiary procedure after subintimal angioplasty and repeat angioplasty. Initial cryoplasty technical success was achieved in 68% (n ϭ 25) of limbs. Of the 12 initial cryoplasty failures, 5 patients were treated with adjunctive balloon angioplasty to attain technical success. Overall procedural success was achieved in 81% (n ϭ 30) of patients. Ten limbs underwent stent placement in the native group. Six stents were placed for flow-limiting dissection and four were placed for a suboptimal result. Despite stent placement, seven limbs still did not attain technical success. These seven technical failures were secondary to dissections and two were due to suboptimal results. In the stent group, cryoplasty was used as the primary intervention in 66% (n ϭ 23 of 35) and as adjunctive intervention in 34% (n ϭ 12 of 35). The interventions performed immediately prior to cryoplasty included intraluminal angioplasty (n ϭ 10), mechanical atherectomy (n ϭ 1), and mechanical thrombolysis with tissue plasminogen activator (n ϭ 1). Cryoplasty was used as the tertiary procedure in 3 patients. The procedural course prior to cryoplasty in these patients was angioplasty and subsequent repeat angioplasty, angioplasty and subsequent mechanical atherectomy, and laser atherectomy and subsequent angioplasty. Eight patients who presented with an occlusion underwent cryoplasty as their first intervention. In 6 of these patients, the wire passed easily, whereas the 2 other patients required a sequential injection analysis technique. Initial cryoplasty technical success was achieved in 71% (n ϭ 25) of limbs. Six initial cryoplasty failures were treated with adjunctive balloon angioplasty to attain technical success. Overall procedural success was achieved in 89% (n ϭ 31) of cases. All four technical failures were secondary to a suboptimal result. Three limbs underwent repeat stent placement in the stent group for a suboptimal result. Despite stent placement, two limbs still did not attain technical success.
There were no statistically significant differences between the native and stent group for either initial cryoplasty technical success or overall procedural success rates.
Outcome analysis. The native group had 30 technically successful interventions; however, 4 patients were lost to follow-up. Therefore, analysis was performed on the 26 remaining patients. The stent group had 31 technically successful interventions without any patients lost to followup. One-year primary patency for the native vs stent group was 17% vs 28%, respectively (P ϭ .18; Fig 1) . The 1-year primary assisted patency for the native vs stent group was 28% vs 47%, respectively (P ϭ .33; Fig 2) . The 1-year secondary patency for the native vs stent group was 41% vs 57% (P ϭ .42), respectively (Fig 3) Freedom from claudication at 1 year for the native vs the stent group was 32% vs 21% (P ϭ .80). Freedom from bypass surgery at 1 and 2 years for the native vs the stent group was 74% and 62% vs 80% and 71%, respectively (P ϭ .63). Six patients in the native group underwent major amputation at a mean of 9.4 months Ϯ 5.5 (3.4-18 months). Four of these 6 patients had CLI, whereas 1 patient was a claudicant. One patient with claudication had an amputation at 1 year after stopping warfarin despite protein S deficiency. Four patients in the stent group underwent major amputation at a mean 17.9 months Ϯ 15 (1.5-31 months). Two of these 4 patients had CLI, whereas 2 patients were claudicants. One patient with severely calcified vessels, ESRD, and poor vessel runoff on her third intervention had an amputation 1½ months postprocedure. The second patient with claudication progressed to amputation 2½ years after cryoplasty, which was the fifth intervention for that leg. There were no periprocedural (Ͻ30 days) deaths in either group. Nine patients died in the native group during follow-up; mean 19 months Ϯ 14 (1.9-38 months). There was only one death in the stent group at 54 months after cryoplasty. The overall survival was 98% and 96% at 1 and 2 years, respectively.
Five patients (14%) in the native group and 7 patients (20%) in the stent group encountered procedural complications. The five complications in the native group were arterial nonflow-limiting dissections (2), arterial microperforation (1), access pseudoaneurysm (1), and distal embolization (1) . Only the patient with distal embolus required conversion to an open procedure. The seven complications in the stent group were access pseudoaneurysms (3), access hematoma (1), postoperative myocardial infarction (1), nonflow-limiting dissection (1), and distal embolization (1) . Again, only the patient with distal embolus required surgery.
DISCUSSION
The restenosis and occlusion rates after endovascular therapy for lower extremity arterial occlusive disease have limited its long-term durability. 1, 2 Several therapies have been used to attempt to improve patency over balloon angioplasty such as stents, drug-eluting stents, atherectomy, and cryoplasty. Cryoplasty works by freezing the surrounding vessel to Ϫ10°C and then allowing the vessel to slowly rewarm. This action causes apoptosis of the smooth muscle cells, alteration in the plaque response to dilation, and reduction of elastic recoil of the vessel wall.
In this study, we share our experience with cryoplasty applied to very difficult lesions. Thirty-seven native artery lesions and 35 stented artery lesions were treated with cryoplasty. We achieved an initial cryoplasty technical success in 68% for the native group and 71% for the stent group. Most studies on cryoplasty reported technical success rates for cryoplasty of 85% to 97%. 3, [6] [7] [8] [9] [10] Our technical success rate with cryoplasty was decreased for several reasons. First, definitions on technical success have varied between studies. Das et al 7 defined technical success if there was Ͻ50% stenosis after intervention, whereas we used a Ͻ30% residual stenosis. Second, we treated very complex lesions in this study compared to most previous studies, which treated mainly Trans Atlantic Inter-Societal Consensus (TASC) A and B lesions. 3, [6] [7] [8] [9] This is emphasized by the mean length of our lesions being 15 cm. Bakken et al 10 also have shown poor initial technical success of 78% with cryoplasty in more challenging lesions. This is consistent with our outcomes. Third, the majority of lesions treated with cryoplasty in our study were reinterventions compared to previous studies in which all were de novo lesions. [3] [4] [5] [6] [7] Interestingly, some of our initial cryoplasty failures responded to balloon angioplasty. This may indicate that some lesions require a higher inflation pressure, which cannot be delivered via cryoplasty.
Our 1-year primary patency for cryoplasty for the native and the stent groups was poor at 17% vs 28%, respectively. These results are far inferior to previously reported patency of 57% to 83% for several reasons. 3,6-10 First, patency definitions have varied significantly between studies. Some have used clinical patency, while others have used target lesion revascularization. Samson et al 8, 9 published two articles on cryoplasty with different definitions of patency. The first publication using target lesion revascularization criteria reported a 1-year patency of 82%, 8 whereas the second report using more traditional definitions found a significant decrease in 1-year patency to 57%. 9 Second, as previously mentioned, this study used cryoplasty for reintervention in ϳ75% of limbs, whereas most studies used cryoplasty for initial treatment. Only Karthick et al 11 evaluated cryoplasty use for reintervention in 10 patients. They reported a 50% and 0% patency at 6 months and 1 year, respectively. Our study showed a trend for worse patency for reinterventions compared to initial therapy.
Third, the lesions in our study were more complex than treated lesions in previous publications. Lesion length in this study averaged 14 cm, whereas in other studies, the lesions ranged from 4 to 8 cm. 3,6-10 Surowiec et al 12 have shown that as lesion length and complexity increases, outcomes of endovascular therapy worsen. Bakken et al 10 reported a primary patency of 69% for cryoplasty use in TASC C and D lesions. They, however, did not report the percentage of lesions in each category, the average lesion length, and used the older TASC classification. Therefore, comparison between the Bakken study and our study still remains difficult. Why would previous interventions, independent of the presence of a stent, alter outcomes? The theory behind cryoplasty is to prevent vessel recoil and neointimal hyperplasia. Patients who have undergone previous interventions, however, have already initiated the process of vessel recoil and neointimal hyperplasia. Therefore, any reintervention with cryoplasty may be too late and unable to fully implement its theoretical benefits.
Multivariate analysis of the native group found a trend for worse outcomes in patients with prior endovascular intervention. In multivariate analysis of the stent group, it seems that female gender and ESRD adversely affect patency. Black et al 13 found renal insufficiency to adversely affect patency after angioplasty.
There are several limitations of our study. First, its retrospective design contributed to incomplete data collection for some preprocedural and postprocedural variables. This could result in underestimation of patency based on clinical follow-up. Second, the use of cryoplasty was determined solely by the surgeon without any specific protocol. This varied use produced a heterogeneous group of treated lesions and patients. This study, however, properly reflects clinical practice. Third, the small numbers in each cohort make subset analysis difficult to interpret. Finally, patency could be overestimated by two of three measures used. There were, however, only a couple of patients whose patency was determined by examination and approximately 50% were determined by arterial duplex. In addition, loss of ABI or pulse could actually occur secondary to vascular disease outside the lesion treated. Therefore, overestimation is less likely.
Despite these limitations, our study does show that cryoplasty use in difficult lesions and for reintervention will result in poor patency and clinical outcomes. The role of cryoplasty in endovascular therapy must be weighed against its increased cost over balloon angioplasty ($1800). Therefore, cryoplasty use in these difficult or recurrent lesions appears to offer minimal benefit.
CONCLUSIONS
Cryoplasty was used in patients with extensive atherosclerotic disease and multiple prior interventions. Cryoplasty provided poor patency rates and poor relief from claudication at 1 year in this population. In patients treated for in-stent restenosis with cryoplasty, patients with ESRD and female gender will likely have worse outcomes. Overall, cryoplasty appears to be an expensive endovascular tool with marginal clinical improvement in our experience. 
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